Kiya K, Uozumi T, Kurisu K, Mikami T, Sugiyama K, Monden S, Maeda H, Matsuoka T, Matsuda Y, Harada K
Dept. of Neurosurgery, Hiroshima University School of Medicine.
Gan To Kagaku Ryoho. 1993 Jun;20(8):1083-6.
Tumor regression occurred in three of 19 patients (15.8%) with malignant glioma during maintenance therapy using MCNU. In two patients, the tumor reduced 5 and 8 months after the initial treatment, respectively. In the remaining patient, though the maintenance therapy was interrupted for a while and consequently the tumor size increased, readministration of MCNU reduced the tumor size two months later. Therefore, since the antitumor activity of MCNU against malignant glioma seems to require a certain time depending on the case, it is recommended that MCNU be given as maintenance therapy for at least half a year.
在使用甲环亚硝脲（MCNU）进行维持治疗期间，19例恶性胶质瘤患者中有3例（15.8%）出现肿瘤消退。在2例患者中，肿瘤分别在初始治疗后5个月和8个月缩小。在其余1例患者中，尽管维持治疗中断了一段时间，肿瘤大小因此增加，但再次给予甲环亚硝脲后，两个月后肿瘤大小缩小。因此，由于甲环亚硝脲对恶性胶质瘤的抗肿瘤活性似乎因病例而异需要一定时间，建议将甲环亚硝脲作为维持治疗至少给予半年。
